Genetic Technologies Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Kevin Camilleri

Chief executive officer

AU$296.1k

Total compensation

CEO salary percentage	87.0%
CEO tenure	3.3yrs
CEO ownership	n/a
Management average tenure	3.3yrs
Board average tenure	5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Kevin Camilleri's remuneration changed compared to Genetic Technologies's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	AU$296k	AU$258k	-AU$12m
Mar 31 2024	n/a	n/a	-AU$12m
Dec 31 2023	n/a	n/a	-AU$13m
Sep 30 2023	n/a	n/a	-AU$12m
Jun 30 2023	AU$281k	AU$233k	-AU$12m
Mar 31 2023	n/a	n/a	-AU$10m
Dec 31 2022	n/a	n/a	-AU$9m
Sep 30 2022	n/a	n/a	-AU$8m
Jun 30 2022	AU$285k	AU$212k	-AU$7m

Compensation vs Market: Kevin's total compensation ($USD184.57K) is below average for companies of similar size in the German market ($USD467.65K).

Compensation vs Earnings: Kevin's compensation has increased whilst the company is unprofitable.

CEO

Kevin Camilleri (47 yo)

3.3yrs

Tenure

AU$296,120

Compensation

Mr. Kevin Camilleri serves as Chief Executive Officer of EasyDNA at Genetic Technologies Limited since August 16, 2021. Mr. Camilleri joined the Genetic Technologies Limited in 2021. He has been Chief Oper...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Kevin Camilleri	Chief Executive Officer of EasyDNA	3.3yrs	AU$296.12k	no data
Mark Ziirsen	CFO & Company Secretary	less than a year	no data	no data
Paul Keith Viney	Consultant	5.4yrs	AU$180.45k	no data
Erika Spaeth	Director of Clinical & Scientific Affairs	no data	no data	no data

3.3yrs

Average Tenure

Experienced Management: DU8's management team is considered experienced (3.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Lindsay Wakefield	Independent Non-Executive Director	10.3yrs	AU$74.88k	0.065% € 2.2k
Peter Rubinstein	Independent Non-Executive Chairman	6.9yrs	AU$150.19k	2.54% € 86.4k
Jerzy Muchnicki	Non-Independent Non-Executive Director	6.9yrs	AU$87.44k	1.55% € 52.6k
Finlay Macrae	Member of Scientific & Medical Advisory Board	3.1yrs	no data	no data
Jon Emery	Member of Scientific & Medical Advisory Board	3.1yrs	no data	no data
Ora Gordon	Member of Scientific & Medical Advisory Board	3.1yrs	no data	no data

5.0yrs

Average Tenure

66yo

Average Age

Experienced Board: DU8's board of directors are considered experienced (5 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/25 12:43
End of Day Share Price	2024/10/16 00:00
Earnings	2024/06/30
Annual Earnings	2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Genetic Technologies Limited is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Marc Kennis	APP Securities Pty Ltd.
Kevin DeGeeter	Ladenburg Thalmann & Company
Chris Kallos	MST Financial Services Pty Limited

Genetic Technologies Management

Management criteria checks 3/4

Key information

Recent management updates

Genetic Technologies Limited Appoints Mark Ziirsen as Chief Financial Officer

Genetic Technologies Limited Announces Resignation of Kathryn Andrews as CFO

Genetic Technologies Limited Announces Resignation of Tony Di Pietro as Chief Financial Officer

Genetic Technologies Limited, Annual General Meeting, Nov 22, 2023

Genetic Technologies Limited, Annual General Meeting, Nov 28, 2022

Genetic Technologies Limited Appoints Tony Di Pietro as Chief Financial Officer

Recent updates

Genetic Technologies Limited(NasdaqCM:GENE) dropped from NASDAQ Composite Index

Genetic Technologies Limited(NasdaqCM:GENE) dropped from NASDAQ Composite Index

Genetic Technologies Limited has withdrawn its Follow-on Equity Offering in the amount of AUD 0.324648 million.

Full year 2024 earnings released: AU$0.091 loss per share (vs AU$0.12 loss in FY 2023)

Full year 2024 earnings released: AU$0.001 loss per share (vs AU$0.12 loss in FY 2023)

Genetic Technologies Limited Announces Global Launch of GeneType on Wholly Owned EasyDNA Platform

Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of AUD 1.71026 million.

Genetic Technologies Limited has filed a Follow-on Equity Offering in the amount of AUD 3.997793 million.

Genetic Technologies Limited Appoints Mark Ziirsen as Chief Financial Officer

Genetic Technologies Limited Announces Resignation of Kathryn Andrews as CFO

Genetic Technologies Limited Share the Power of the geneType Test in Identifying Risk and Improving the Health of Populations Worldwide

Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of $2 million.

New minor risk - Shareholder dilution

Genetic Technologies Limited has filed a Follow-on Equity Offering in the amount of $11.2056 million.

Genetic Technologies Limited has filed a Follow-on Equity Offering in the amount of $2 million.

Genetic Technologies Limited Establishes Clinical Implementation Study with Breast Screen Centres Across New York, Miami and Houston

Genetic Technologies Limited to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare

New major risk - Revenue and earnings growth

Genetic Technologies Limited Announces Resignation of Tony Di Pietro as Chief Financial Officer

Genetic Technologies Regains Compliance with Nasdaq Minimum Bid Price Requirement

New major risk - Market cap size

Genetic Technologies Limited, Annual General Meeting, Nov 22, 2023

Genetic Technologies Limited Announces the Expanded GeneType Multi-Risk Test Is Now Available to Order in Australia

Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2022)

New minor risk - Financial data availability

First half 2023 earnings released: AU$0.001 loss per share (vs AU$0 in 1H 2022)

Genetic Technologies Limited Announces Publication Highlights Genetype’S Ability to Detect Breast Cancer Earlier and Provide Data for Risk Stratification

Genetic Technologies Limited Provides Further Update on Comprehensive Risk Test for Breast & Ovarian Cancer

Genetic Technologies Limited to Launch World’s First Comprehensive Risk Test for Breast & Ovarian Cancer

Genetic Technologies Limited Published in Plus One for Cvd & Type 2 Diabetes

Genetic Technologies Limited, Annual General Meeting, Nov 28, 2022

Genetic Technologies Limited Appoints Tony Di Pietro as Chief Financial Officer

Full year 2022 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2021)

Genetic Technologies Limited (ASX:GTG) completed the acquisition of eCommerce Business and Distribution Rights of AffinityDNA from Affinity DNA Limited.

Genetic Technologies Limited Announces Resignation of Michael Tonroe as Company Secretary

Genetic Technologies Limited Commences Initial Implementation of its geneType Risk Assessment Test at 16 Medical Practices Across the East Coast of Australia

Genetic Technologies Limited Announces the Completion of an Independently Developed and Validated Customisable Budget Impact Model

Genetic Technologies Limited (ASX:GTG) entered into an agreement to acquire eCommerce Business and Distribution Rights of AffinityDNA from Affinity Dna Limited for £0.555 million

Genetic Technologies Limited Announces GeneType Multi-Test Approves for Commercial Release

High number of new and inexperienced directors

Full year 2021 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2020)

Genetic Technologies Limited (ASX:GTG) completed the acquisition of General Genetics Corporation from BelHealth Investment Fund, L.P. managed by BelHealth Investment Partners, LLC.

Company Secretary Justyn Stedwell has left the company

Genetic Technologies Limited Confirms the Launch of GTG's Covid-19 Serious Disease Risk Test (`Covid-19 Risk Test') by US Based Infinity Biologix LLC

Genetic Technologies Limited Provides COVID-19 Risk Test Launch Update

Genetic Technologies Limited Signs 3-Year US Licence Agreement for COVID Risk Test

Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of $6.5625 million.

Genetic Technologies Limited Provides Update on Its COVID-19 Disease Severity Risk Test and Expansion into Germline Testing

Genetic Technologies Limited Announces Management Changes

Genetic Technologies Secures US and ANZ Distribution Rights for PREDICTIX

Genetic Technologies Limited, Annual General Meeting, Dec 10, 2020

Genetic Technologies Limited to Report Q4, 2020 Results on Oct 30, 2020

Full year earnings released - €0.0015 loss per share

Genetic Technologies Provides Update on COVID-19 Risk Test

Full year earnings released - €0.0015 loss per share

Genetic Technologies Receives Delisting Notification Letter from Nasdaq

Full year earnings released - €0.0015 loss per share

Genetic Technologies Regains Compliance with Nasdaq Stockholders Equity Requirement

Full year earnings released - €0.0015 loss per share

Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of $5.125 million.

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age